YOU: The Owner's Manual

Dr. Roizen talks about the latest health headlines that YOU need to know.  

 

Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open in August 2022.Using data from nine clinical trials, this study provides one of the most comprehensive analyses of interstitial lung disease diagnosis and treatment in patients who received an antibody-drug conjugate known as T-DXd, from a class of drugs designed as a targeted therapy for treating cancers.The retrospective review examined 1,150 heavily pre-treated patients with breast, lung, gastric, colorectal, or other cancers across nine studies treated with T-DXd, also known as ENHERTU®.Senior author Charles Powell, MD, MBA, joins us today to discuss the findings. He is the Professor of Medicine and System Division Chief for Pulmonary, Critical Care, and Sleep Medicine at the Icahn School of Medicine at Mount Sinai in New York and the Medical Director of Respiratory Therapy at Mount Sinai Hospital.  He also directs research programs focused on the early detection of lung interstitial disease and airway disease.

Dr. Roizen talks about the latest health headlines that YOU need to know.  

 

A diagnosis of lung cancer used to be a diagnosis of death. Not anymore.

Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open in August 2022.

Using data from nine clinical trials, this study provides one of the most comprehensive analyses of interstitial lung disease diagnosis and treatment in patients who received an antibody-drug conjugate known as T-DXd, from a class of drugs designed as a targeted therapy for treating cancers.

The retrospective review examined 1,150 heavily pre-treated patients with breast, lung, gastric, colorectal, or other cancers across nine studies treated with T-DXd, also known as ENHERTU®.

Senior author Charles Powell, MD, MBA, joins us today to discuss the findings. He is the Professor of Medicine and System Division Chief for Pulmonary, Critical Care, and Sleep Medicine at the Icahn School of Medicine at Mount Sinai in New York and the Medical Director of Respiratory Therapy at Mount Sinai Hospital.  He also directs research programs focused on the early detection of lung interstitial disease and airway disease.

Getting together as a family when a cherished loved one was lost during the year and won’t be there, can feel daunting. Not only does the thought bring sadness, but it can also bring back memories of others who have died.

Drs. Elena Lister and Michael Schwartzman, authors of the new book "Giving Hope: Conversations with Children About Illness, Death, and Loss," advocate this is a natural part of the grieving process and should be faced in a straightforward way. People don’t like to talk about sad things and often parents feel that bringing up something painful will initiate pain in their child. However, most children are aware of the loss of a special person and are feeling the pain too.

Dr. Elana Lister joins us today to share how talking through it helps people find strength and resilience through seeing others feel the same, and helps a child not be left alone with difficult emotions to manage.

Dr. Roizen talks about the latest health headlines that YOU need to know.  

 

To be an emergency room doctor is to be a professional listener to stories. Each patient presents a story; finding the heart of that story is the doctor's most critical task.

More technology, more tests, and more data won't work if doctors get the story wrong. When caring for others can feel like venturing into unchartered territory without a map, empathy, creativity, imagination, and thinking like a writer become the cornerstones of clinical care. In Tornado of Life, ER physician Jay Baruch shares these struggles in a series of short, powerful, and affecting essays that invite the reader into stories rich with complexity and messiness.

Patients come to the ER with lives troubled by scales of misfortune that have little to do with disease or injury. ER doctors must be problem-finders before they are problem-solvers. Baruch describes, among other things, the emergency of loneliness (invoking Chekhov, another doctor-writer); his own (frightening) experience as a patient; the patient who demanded a hug; and emergency medicine during COVID-19. These stories often end without closure or solutions. The patients are discharged into the world. But if they're lucky, the doctor has listened to their stories as well as treated them.

Dr. Roizen talks about the latest health headlines that YOU need to know.  

 

Dr. Roizen talks about the latest health headlines that YOU need to know.  

 

Rare diseases are also called ‘orphan diseases,’ so named because they were long abandoned (or orphaned) by a profit-driven pharmaceutical industry. So why a book about orphan drugs, which by definition treat only rare diseases? Did they really trigger a revolution important enough to care about? And if so, why is that so little known? In fact, orphan drugs have revolutionized society, for reasons ranging from the deeply personal to the broader cultural and political.

Rare diseases deserve our attention because they’re merciless, causing families often far worse human suffering than common diseases. And unlike many common diseases, few can be prevented or treated by a good diet or exercise. Perhaps most importantly, a rare genetic disease could someday strike any family—and an orphan drug become of utmost urgency to anyone with a child or grandchild, niece or nephew.

A biotechnology executive, Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward, to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow.